Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Background: To investigate the role of persistent angiotensin activity despite
angiotensinconverting enzyme inhibitor therapy in the progression of heart failure, the …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Aims To investigate the effect of valsartan in the Valsartan‐Heart Failure Trial (Val‐HeFT)
when added to angiotensin‐converting enzyme inhibitor (ACEi) alone in patients with heart …

Objective: To evaluate the effect on cardiac hemodynamic parameters of valsartan in
patients with chronic stable congestive heart failure previously untreated with ACE inhibitors …

Background—Aldosterone has been implicated in the progression of heart failure. The
Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long …

Objectives: We sought to determine the effect of angiotensin receptor blockers (ARBs) on
mortality and hospitalization in patients with heart failure (HF). Background: There is …

Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

Summary Background Angiotensin-receptor blockers (ARBs) are effective treatments for
patients with heart failure, but the relation between dose and clinical outcomes has not been …

Clinical studies of heart failure utilizing losartan, an angiotensin-II receptor antagonist, found
that this drug is well tolerated and demonstrates hemodynamic, neurohormonal, and …